

Synthesis of 4-Aminopyrimidines from 1,2,4-Oxadiazoles, II¹⁾**A General Method for the Preparation of 4-Substituted 6,7-Dihydro-9,10-dialkoxy-2*H*-pyrimido[6,1-*a*]isoquinolin-2-imine Hydrochlorides**Dezső Korbonits^{*,†}, Pál Kiss^{*}, Imre Bata^{*}, Gergely Héja^{*}, Kálmán Simon^{*}, and Pál Kolonits[†]Chinoin Research Centre^{*}, P.O.B. 110, H-1325, Budapest, HungaryInstitute of Organic Chemistry, Technical, University[†], P.O.B. 91, Budapest, Hungary

Received January 19, 1987

5'-Substituted 1-[(1,2,4-oxadiazol-3-yl)methyl]-3,4-dihydroisoquinolines (7) were reduced by NaBH₄ selectively to give the corresponding tetrahydroisoquinolines (8) which underwent ring isomerization to pyrazolo[5,1-*a*]isoquinolines⁴⁾ (9). Catalytic hydrogenation of 7 in the presence of hydrogen chloride, in turn, gave by reductive cleavage of the N—O bond of the 1,2,4-oxadiazole ring and subsequent dehydration, quite generally, 4-substituted pyrimido[6,1-*a*]isoquinolin-2-imine hydrochlorides (11).


Synthese von 4-Aminopyrimidinen aus 1,2,4-Oxadiazolen, II¹⁾. — Eine allgemeine Methode zur Herstellung von 4-substituierten 6,7-Dihydro-9,10-dialkoxy-2*H*-pyrimido[6,1-*a*]isoquinolin-2-imin-hydrochloriden

Während die Reduktion von 5'-substituierten 1-[(1,2,4-Oxadiazol-3-yl)methyl]-3,4-dihydroisoquinolinen (7) mit NaBH₄ selektiv zu den entsprechenden Tetrahydroisoquinolinen 8 und durch nachfolgende Ringisomerisierung zu Pyrazolo[5,1-*a*]isoquinolinen 9 führte⁴⁾, ergab die katalytische Hydrierung von 7 in Anwesenheit von Chlorwasserstoff durch reduktive Spaltung der N—O-Bindung des 1,2,4-Oxadiazolrings und nachfolgende spontane Dehydratisierung ganz allgemein 4-substituierte Pyrimido[6,1-*a*]isoquinolin-2-imin-hydrochloride (11).

Earlier we have reported the synthesis of some 2- and 4-unsubstituted pyrimido[6,1-*a*]isoquinolines^{2a,b)} among which several compounds with a hypotensive action were found^{2c)}. According to the recent literature 2-imino-pyrimido[6,1-*a*]isoquinolin-4-ones have valuable pharmacological properties. In these compounds the 2-imino or 2-amino groups have been elaborated by transforming pyrimido[6,1-*a*]isoquinolin-2-ones into the corresponding 2-halides followed by amination of this function³⁾.

The purpose of the present study was to extend our method for the preparation of condensed 4-aminopyrimidines (2, 4) by hydrogenolysis of 3-(2-aminoaryl)-1,2,4-oxadiazoles (1, 3)¹⁾ to the synthesis of 4-substituted 2-iminopyrimido[6,1-*a*]isoquinolines (11). In this procedure the amino or imino group is formed by an intramolecular reductive condensation (Scheme 1).

Scheme 1




Recently we described⁴⁾ the NaBH₄ reduction of 1-[(1,2,4-oxadiazol-3-yl)methyl]-3,4-dihydroisoquinolines 7, readily available via the amides 5 and 6⁵⁾. This involves the uptake of 1 mol of hydrogen to give the tetrahydroisoquinolines 8, which undergo spontaneously or on brief heating ring isomerization to 2-(acylamino)pyrazolo[5,1-*a*]isoquinolines (9). This reaction is analogous to the ring isomerization of the related 1,2,4-oxadiazoles⁶⁾. It has to be noted, that, according to NMR (taken in DMSO), 7 as a base is present in solution in the enamine form containing an exocyclic double bond, while the salts of 7 exist as protonated imines.

According to our present study the reduction of 7 can be carried out with a chemo selectivity quite different from that reported earlier⁴⁾. If the oxadiazoles 7a—z are subjected to catalytic hydrogenation in dilute ethanolic hydrogen chloride over palladium-carbon, first the N—O bond of the 1,2,4-oxadiazole ring suffers hydrogenolysis followed in a second step by immediate cyclization and spontaneous dehydration of the intermediate acylamidines (10) to give the 4-substituted 6,7-dihydro-9,10-dialkoxy-2*H*-pyrimido[6,1-*a*]isoquinolin-2-imine hydrochlorides 11a—z⁷⁾.

For compounds 11 several other tautomeric forms can be envisaged, but under aqueous acidic conditions they exist probably as 2-amino-6,7-dihydro-9,10-dialkoxypyrimido[6,1-*a*]isoquinolinium chlorides. The relative stability of the aromatic pyrimidinium ring may explain the fact that whereas catalytic hydrogenation of the related pyrimido[6,1-*a*]isoquinolines according to our previous experiences resulted, in the saturation of the pyrimidine ring^{2a)}, in the transformation 7→11 and under the present conditions hydrogen uptake stopped after the consumption of one mol.

Scheme 2



	R ¹	R ²		R ¹	R ²
a	Me	Me	n	Et	n-heptyl
b	Me	PhCH ₂	o	Et	2-morpholinoethyl
c	Me	3,4-(MeO) ₂ C ₆ H ₃ CH ₂	p	Et	cyclohexyl
d	Me	Ph	q	Et	3,4-(MeO) ₂ C ₆ H ₃ CH ₂
e	Me	4-MeC ₆ H ₄	r	Et	Ph
f	Me	4-MeOC ₆ H ₄	s	Et	4-MeC ₆ H ₄
g	Me	3,4,5-(MeO) ₃ C ₆ H ₂	t	Et	4-MeOC ₆ H ₄
h ⁺	Me	4-R ³ OC ₆ H ₃	u	Et	3,4,5-(MeO) ₃ C ₆ H ₂
i	Me	3-pyridyl	v ⁺	Et	4-R ³ OC ₆ H ₃
j	Me	4-pyridyl	w	Et	1-naphthyl
k	Et	Me	x	Et	2-pyridyl
l	Et	Et	y	Et	3-pyridyl
m	Et	n-pentyl	z	Et	4-pyridyl

⁺ For 6h, v and 7h, v R³ = PhCH₂, for 11h, v R³ = H

By variation of the ester component (R²CO₂Et) serving to elaborate the 1,2,4-oxadiazole ring of the amide 6, the key intermediates 7 not only permit the preparation of the pyrazolo[5,1-a]isoquinolines 9 by simple reduction and ring transformation⁴⁾, but as shown here, modification of the reduction provides a selective method for the preparation of pyrimido[6,1-a]isoquinolines of type 11 containing a broad variety of R² groups.

The present results extend the scope of our investigations on 4-aminopyrimidines, condensed pyrimidines, and on the ring transformation of 1,2,4-oxadiazoles^{1,2,4,6,8)}.

Thanks are due to Miss V. Harangozó for technical assistance, to Dr. V. Kovács for recording the IR spectra, and to Dr. I. Remport for elemental analyses.

Experimental

IR spectra: Unicam SP-100 and Spectromom 2000 in KBr. — ¹H- and ¹³C-NMR spectra: Jeol FX-100 at 100 and 25 MHz, respectively. In the Tables only characteristic ¹H-NMR data are quoted. Melting points were not corrected.

5-Substituted 3-[[2-(3,4-Dialkoxyphenyl)ethyl]carbamoylmethyl]-1,2,4-oxadiazoles (6) (General method)^{4,5)}. To a solution of 2-[[2-(3,4-dialkoxyphenyl)ethyl]carbamoyl]acetamide oxime (5) (75 mmol) in dry ethanol (300 ml) the appropriate carboxylic ester (150

mmol) and a solution of sodium (1.72 g, 75 mmol) in ethanol (75 ml) was added. After refluxing for 4 h the mixture was cooled, the product separated, washed with water (300 ml), and dried. Compounds 6m and 6n were recrystallized from hexane, all the others from ethanol. M.p.'s, yields, IR spectroscopic data, and elementary analyses see Table 1, ¹H-NMR data Table 4.

Table 1. Yields, melting points, IR spectral and analytical data of compounds 6a–c and 6g–z. The data of 6d–f were given earlier⁴⁾

No.	Yield (%)	M.p. (°C)	ν _{max} /cm ⁻¹	Formula Mol. Wt.	Found (%) (Required)		
					C	H	N
6a	61	127	3295, 1652	C ₁₅ H ₁₃ O ₂ N ₃ 305.32	57.96 (59.00)	6.25 (6.27)	13.72 (13.76)
6b	39	152 ^{a)}	3180, 1635	C ₂₁ H ₂₃ O ₂ N ₃ 381.41	66.00 (66.13)	6.02 (6.08)	10.97 (11.02)
6c	67	124	3290, 1660	C ₂₃ H ₂₇ N ₃ O ₆ 441.47	62.65 (62.57)	6.08 (6.16)	9.31 (9.51)
6d	55	152	3220, 1640	C ₂₃ H ₂₇ N ₃ O ₇ 457.47	60.21 (60.38)	5.84 (5.73)	9.29 (9.18)
6e	56	144	3340, 1662, 1620	C ₂₇ H ₂₇ N ₃ O ₅ 473.51	68.31 (68.48)	5.60 (5.75)	8.80 (8.87)
6f	63	131	3295, 1645	C ₁₉ H ₂₀ N ₃ O ₄ 368.36	61.98 (61.94)	5.40 (5.47)	15.15 (15.21)
6g	52	162	3340, 1653	C ₁₉ H ₂₀ N ₃ O ₄ 367.36	62.30 (61.94)	5.46 (5.47)	15.23 (15.21)
6h	71	99	3320, 2950, 1652	C ₁₇ H ₂₃ O ₂ N ₃ 333.37	61.10 (61.24)	6.70 (6.95)	12.55 (12.60)
6i	40	106	3310, 3000, 1650	C ₁₀ H ₁₂ O ₂ N ₃ 347.40	52.55 (52.23)	7.16 (7.25)	12.05 (12.10)
6m	80	77 (from hexane)	3300, 2910, 1650	C ₂₁ H ₂₁ N ₃ O ₄ 379.45	64.52 (64.76)	7.95 (8.02)	10.63 (10.79)
6n	72	76 (from hexane)	3400, 2950, 1630	C ₂₃ H ₂₅ O ₂ N ₃ 417.53	66.03 (66.16)	8.32 (8.45)	10.01 (10.06)
6o	71	89 (from hexane)	3265, 2975, 1640	C ₂₂ H ₂₂ O ₂ N ₃ 432.51	61.05 (61.09)	7.43 (7.46)	12.91 (12.95)
6p	45	109	3310, 2950, 1650	C ₂₂ H ₂₁ N ₃ O ₄ 401.49	65.86 (65.01)	7.66 (7.70)	10.60 (10.47)
6q	74	121	3320, 1655	C ₂₅ H ₃₁ N ₃ O ₆ 469.52	63.90 (63.95)	6.56 (6.66)	8.97 (9.05)
6r	71	137	3290, 1642	C ₂₂ H ₂₅ N ₃ O ₄ 395.44	67.03 (66.82)	6.40 (6.37)	10.89 (10.63)
6s	61	152	3340, 1665	C ₂₃ H ₂₇ N ₃ O ₄ 409.47	67.38 (67.46)	6.73 (6.65)	10.29 (10.26)
6t	78	142	3300, 1650	C ₂₃ H ₂₇ N ₃ O ₅ 425.47	65.10 (64.92)	6.50 (6.40)	9.72 (9.55)
6u	49	148	3360, 1630	C ₂₅ H ₃₁ N ₃ O ₇ 495.52	61.23 (61.04)	6.33 (6.64)	8.70 (9.66)
6v	47	141	3320, 1662, 1620	C ₂₉ H ₃₁ N ₃ O ₅ 501.56	69.14 (69.44)	6.02 (6.23)	8.36 (8.30)
6w	62	160	3320, 1658	C ₂₆ H ₂₇ N ₃ O ₄ 445.50	70.00 (70.09)	6.13 (6.11)	9.07 (9.43)
6x	47	128	3300, 1655	C ₂₁ H ₂₄ N ₃ O ₄ 396.43	63.70 (63.62)	6.15 (6.10)	14.15 (14.13)
6y	59	129	3295, 1650	C ₂₁ H ₂₄ N ₃ O ₄ 396.43	63.45 (63.62)	6.00 (6.10)	14.05 (14.13)
6z	37	136	3320, 1652	C ₂₁ H ₂₄ N ₃ O ₄ 396.43	63.42 (63.62)	5.95 (6.10)	14.21 (14.13)

^{a)} Ref.⁵⁾ 153 °C.

5'-Substituted 3,4-Dihydro-6,7-dialkoxy-1-[(1,2,4-oxadiazol-3-yl)methyl]isoquinolines (7) (General method)^{4,5)}. To a hot solution of oxadiazole 6 (60 mmol) in chloroform (200 ml) phosphoryl chloride (55.2 g, 33 ml, 360 mmol) was added dropwise. Boiling was continued for another 3 h. Then excess reagent was distilled off, the residue dissolved in chloroform, and the solution made alkaline with conc. ammonium hydroxide under cooling. The solution was thoroughly extracted with water, evaporated and the residue crystallized. M.p.'s., solvents of crystallization, yields, IR spectroscopic data, and elementary analyses were compiled in Table 2, ¹H-NMR data in Table 5.

Table 2. Yields, melting points, IR spectral and analytical data of compounds 7a–c and 7g–z. The data of 7d–f were given earlier⁴⁾

No	Yield (%)	M.p. (°C) r.s.a)	$\nu_{\text{max}}/\text{cm}^{-1}$	Formula Mol. Wt.	Found (%) (Required)		
					C	H	N
7a	71	122 B	3335, 1640, 1620	$\text{C}_{15}\text{H}_{17}\text{N}_3\text{O}_3$ 287.31	62.73 (62.70)	6.00 (5.97)	14.60 (14.63)
7b	61	145 ^{b)} B	3295, 1630, 1622	$\text{C}_{21}\text{H}_{25}\text{N}_3\text{O}_3$ 363.40	69.56 (69.40)	5.75 (5.82)	11.60 (11.56)
7c	70	145 B	3300, 1630, 1610	$\text{C}_{23}\text{H}_{29}\text{N}_3\text{O}_5$ 423.45	65.36 (65.23)	5.97 (5.95)	9.95 (9.92)
7d	56	150 B	3295, 1630	$\text{C}_{23}\text{H}_{29}\text{N}_3\text{O}_6$ 439.45	62.83 (62.85)	5.70 (5.73)	9.60 (9.56)
7e	58	195 A	3350, 1640, 1620	$\text{C}_{27}\text{H}_{31}\text{N}_3\text{O}_4$ 455.49	71.08 (71.19)	5.40 (5.33)	9.30 (9.22)
7f	41	169 A	3360, 1630, 1610	$\text{C}_{19}\text{H}_{17}\text{N}_3\text{O}_3$ 350.36	65.11 (65.13)	5.04 (5.10)	15.20 (15.99)
7g	56	102 A	3345, 1625, 1605	$\text{C}_{19}\text{H}_{17}\text{N}_3\text{O}_3$ 350.36	65.02 (65.13)	5.30 (5.10)	16.02 (15.99)
7h	72	134 B	3305, 1622, 1604	$\text{C}_{17}\text{H}_{21}\text{N}_3\text{O}_3$ 315.36	64.70 (64.74)	6.59 (6.71)	13.27 (13.32)
7i	93	93 B	3350, 1630, 1612	$\text{C}_{18}\text{H}_{23}\text{N}_3\text{O}_3$ 329.38	65.65 (65.63)	7.16 (7.04)	12.73 (12.76)
7j	64	171 ^{c)} BA 1610	2960, 2560, 1663	$\text{C}_{21}\text{H}_{29}\text{N}_3\text{O}_3 \cdot \text{HCl}$ 407.93	62.00 (61.83)	7.50 (7.41)	10.30 ^{d)} (10.30)
7k	57	151 ^{d)} BA 1612	2950, 2560, 1660	$\text{C}_{23}\text{H}_{33}\text{N}_3\text{O}_3 \cdot \text{HCl}$ 435.90	63.50 (63.36)	8.01 (7.06)	9.40 ^{d)} (9.64)
7l	60	141 A	3320, 1640, 1595	$\text{C}_{22}\text{H}_{30}\text{N}_3\text{O}_4$ 414.49	64.00 (63.75)	7.23 (7.30)	13.46 (13.52)
7m	79	101 B	3375, 2950, 1630	$\text{C}_{22}\text{H}_{29}\text{N}_3\text{O}_3$ 383.47	68.30 (68.90)	7.49 (7.62)	10.90 (10.96)
7n	34	163 A	3350, 2950, 1635	$\text{C}_{25}\text{H}_{29}\text{N}_3\text{O}_5$ 451.50	66.45 (66.50)	6.43 (6.47)	9.28 (9.31)
7o	74	137 A	3355, 1640, 1617	$\text{C}_{22}\text{H}_{23}\text{N}_3\text{O}_3$ 377.42	70.28 (70.01)	6.13 (6.14)	11.20 (11.13)
7p	77	154 A	3400, 1640, 1622	$\text{C}_{25}\text{H}_{29}\text{N}_3\text{O}_3$ 391.45	70.28 (70.57)	6.61 (6.44)	10.95 (10.74)
7q	79	131 A	3350, 1630, 1618	$\text{C}_{25}\text{H}_{25}\text{N}_3\text{O}_4$ 407.45	67.36 (67.79)	6.12 (6.10)	10.49 (10.31)
7r	71	158 A	3350, 1642, 1615	$\text{C}_{25}\text{H}_{29}\text{N}_3\text{O}_6$ 467.50	64.68 (64.22)	6.30 (6.25)	8.75 (8.99)
7s	51	150 A	3320, 1630, 1612	$\text{C}_{25}\text{H}_{29}\text{N}_3\text{O}_4$ 439.54	71.93 (72.03)	5.99 (6.05)	8.72 (8.69)
7t	77	150 A	3355, 1636, 1616	$\text{C}_{26}\text{H}_{29}\text{N}_3\text{O}_3$ 427.48	72.83 (73.05)	5.92 (5.89)	9.92 (9.93)
7u	62	139 A	3325, 1625, 1605	$\text{C}_{21}\text{H}_{22}\text{N}_3\text{O}_3$ 378.42	66.49 (66.65)	5.82 (5.86)	14.63 (14.81)
7v	58	169 A	3305, 1630, 1605	$\text{C}_{21}\text{H}_{22}\text{N}_3\text{O}_3$ 378.42	66.35 (66.65)	5.85 (5.86)	14.57 (14.01)
7w	57	166 A	3370, 1640, 1610	$\text{C}_{21}\text{H}_{22}\text{N}_3\text{O}_3$ 378.42	66.77 (66.65)	5.78 (5.06)	14.78 (14.81)

a) Recrystallization solvents: E = EtOH, EA = EtOAc, A = CH_3CN . — b) Ref.⁵⁾ 145°C. — c) As monohydrochloride. — d) Cl Found 8.80 (required 8.69). — e) Cl Found 8.02 (required 8.13).

6,7-Dihydro-9,10-dimethoxy-4-methyl-2H-pyrimido[6,1-a]isoquinolin-2-imine Hydrochloride (11a): 7a (2.87 g, 10 mmol) was hydrogenated over 8% palladiumcarbon (0.2 g) in a mixture of ethanol (200 ml) and 10% hydrochloric acid (10 ml). The uptake of hydrogen was complete within 30 min. Filtration, evaporation, and crystallization of the residue from water gave 11a (2.34 g, 72%), m.p. 275°C (dec.). — IR: 3400 cm^{-1} , 3200, and 1630. — ^1H NMR ($[\text{D}_6]\text{DMSO}$): δ = 2.68 (s, 3H, CH_3), 3.06 (t, J = 6.5 Hz, 2H, 7-H), 3.86 (s, 3H, OCH_3), 3.87 (s, 3H, OCH_3), 4.24 (t, J = 6.5 Hz, 2H, 6-H), 7.09 (s, 1H, 8-H), 7.24 (s, 1H, 11- or 1-H), 7.38 (s, 1H, 1- or 11-H), 8.70 (bs, 1H, NH-2 or NH-3), 8.72 (bs, 1H, NH-3 or NH-2). — ^{13}C NMR ($[\text{D}_6]\text{DMSO}$): δ = 23.36 (CH_3), 26.10 (C-7), 45.99 (C-6), 56.14 (2 OCH_3), 97.50 (C-7), 109.00 (C-11), 111.13 (C-8), 117.51 (C-11a), 130.55 (C-7a), 148.60 (C-9 or C-10), 149.80 (C-10 or C-9), 153.05 (C-11b), 162.82 (C-4 or C-2), 163.26 (C-2 or C-4).

$\text{C}_{15}\text{H}_{18}\text{ClN}_3\text{O}_2 \cdot \text{H}_2\text{O}$ (325.8)

Calcd. C 55.29 H 6.19 Cl 10.88 N 12.90

Found C 55.32 H 6.08 Cl 10.94 N 12.75

6,7-Dihydro-9,10-dimethoxy-4-phenyl-2H-pyrimido[6,1-a]isoquinolin-2-imine Hydrochloride (11d): 7d⁵⁾ (3.49 g, 10 mmol) was hydrogenated as described for 11a to give 11d (3.02 g, 78%), m.p. 232°C (from H_2O). — IR: 3380 cm^{-1} , 3210, 1655. — ^1H NMR ($[\text{D}_6]\text{DMSO}$): δ = 3.03 (m, 2H, 7-H), 3.87 (s, 6H, 2 OCH_3), 4.12 (m, 2H, 6-H), 7.09 (s, 1H, 8-H), 7.64 (s, 1H, 11- or 1-H), 7.58 (s, 1H, 1- or 11-H), 7.6–7.9 (m, 5H, Ph), 8.96 (bs, 1H, NH-2 or NH-3), 9.23 (bs, 1H, NH-3 or NH-2). — ^{13}C NMR ($[\text{D}_6]\text{DMSO}$): δ = 23.36 (C-7), 48.59 (C-6), 56.20 (OCH_3), 56.26 (OCH_3), 98.55 (C-1), 109.00 (C-11), 111.19 (C-8), 117.95 (C-11a), 128.86 (C-2' or C-3'), 128.95 (C-3' or C-2'), 130.79 (C-7a), 131.26 (C-4'), 133.16 (C-1'), 148.63 (C-9 or C-10), 150.07 (C-10 or C-9), 153.05 (C-11b), 162.06 (C-4 or C-2), 163.26 (C-2 or C-4).

$\text{C}_{20}\text{H}_{20}\text{ClN}_3\text{O}_2 \cdot \text{H}_2\text{O}$ (387.9)


Calcd. C 61.93 H 5.72 Cl 9.14 N 10.83

Found C 61.73 H 5.81 Cl 9.00 N 10.90

Table 3. Yields, melting points, IR spectral and analytical data of compounds 11b, c, e–z

No	Yield (%)	M.p. (°C) r.s.a)	$\nu_{\text{max}}/\text{cm}^{-1}$	Formula Mol. Wt.	Found (%) (Required)			
					C	H	N	Cl
11b	64	252 B-W 1:1	3300, 3200, 1630	$\text{C}_{21}\text{H}_{21}\text{N}_3\text{O}_2 \cdot \text{HCl} \cdot \text{H}_2\text{O}$ 401.88	62.62 (62.76)	6.32 (6.01)	10.48 (10.45)	8.07 (8.82)
11c	48	223 B	3340, 3110, 1650	$\text{C}_{23}\text{H}_{25}\text{N}_3\text{O}_2 \cdot \text{HCl} \cdot \text{H}_2\text{O}$ 461.93	59.65 (59.80)	6.10 (6.11)	8.81 (9.10)	7.65 (7.60)
11d	72	255 B	3420, 3270, 1660	$\text{C}_{21}\text{H}_{21}\text{N}_3\text{O}_2 \cdot \text{HCl} \cdot \text{H}_2\text{O}$ 401.88	62.90 (62.76)	5.95 (6.02)	10.35 (10.46)	9.01 (8.02)
11e	69	248 B	3420, 3220, 1630	$\text{C}_{21}\text{H}_{21}\text{N}_3\text{O}_2 \cdot \text{HCl} \cdot \text{H}_2\text{O}$ 417.90	60.21 (60.35)	5.80 (5.79)	10.17 (10.06)	8.37 (8.49)
11f	60	259 B	3320, 3140, 1625	$\text{C}_{23}\text{H}_{25}\text{N}_3\text{O}_2 \cdot \text{HCl} \cdot \text{H}_2\text{O}$ 478.03	58.16 (57.80)	5.65 (5.90)	9.96 (0.79)	7.47 (7.42)
11g	63	297 B	3360, 3150, 1660	$\text{C}_{20}\text{H}_{19}\text{N}_3\text{O}_2 \cdot \text{HCl} \cdot \text{H}_2\text{O}$ 395.04	61.99 (62.25)	5.36 (5.22)	10.60 (10.09)	9.07 (9.19)
11h	44	246 B	3360, 3170, 1660	$\text{C}_{19}\text{H}_{17}\text{N}_3\text{O}_2 \cdot 2\text{HCl} \cdot 2\text{H}_2\text{O}$ 443.32	51.72 (51.47)	5.31 (5.46)	12.63 (12.64)	
11i	82	270 B	3410, 3250, 1670	$\text{C}_{19}\text{H}_{17}\text{N}_3\text{O}_2 \cdot 2\text{HCl}$ 407.29	56.24 (56.03)	5.07 (4.95)	13.67 (13.76)	17.43 (17.41)
11j	70	285 B	3420, 3270, 1672	$\text{C}_{17}\text{H}_{21}\text{N}_3\text{O}_2 \cdot \text{HCl} \cdot \text{H}_2\text{O}$ 353.04	57.51 (57.70)	6.03 (6.04)	12.07 (11.08)	9.95 (10.02)
11k	50	243 A	3400, 3200, 1640	$\text{C}_{18}\text{H}_{21}\text{N}_3\text{O}_2 \cdot \text{HCl} \cdot \text{H}_2\text{O}$ 367.87	53.70 (53.76)	7.15 (7.12)	11.35 (11.42)	9.82 (9.64)
11l	61	244 P	3300, 3100, 2950	$\text{C}_{21}\text{H}_{25}\text{N}_3\text{O}_2 \cdot \text{HCl} \cdot \text{H}_2\text{O}$ 409.95	61.70 (61.52)	8.16 (7.87)	9.97 (10.25)	8.49 (8.65)
11m	48	225 B-D 1:3	3300, 3100, 2920	$\text{C}_{23}\text{H}_{33}\text{N}_3\text{O}_2 \cdot \text{HCl} \cdot \text{H}_2\text{O}$ 438.00	62.99 (63.07)	8.39 (8.29)	9.50 (9.59)	8.02 (8.10)
11n	86	195 B-D 1:6	3200, 3100, 2950	$\text{C}_{22}\text{H}_{31}\text{N}_3\text{O}_2 \cdot 2\text{HCl} \cdot 2\text{H}_2\text{O}$ 507.45	52.14 (52.07)	7.00 (7.15)	11.10 (11.04)	14.05 (13.97)
11o	65	228 B	3300, 3150, 2920	$\text{C}_{22}\text{H}_{29}\text{N}_3\text{O}_2 \cdot \text{HCl}$ 403.95	63.19 (63.62)	6.49 (6.41)	10.30 (8.90)	8.69 (7.51)
11p	56	250 B	3320, 3050, 1660	$\text{C}_{25}\text{H}_{29}\text{N}_3\text{O}_2 \cdot \text{HCl}$ 471.97	63.19 (63.62)	6.49 (6.41)	8.99 (8.90)	7.21 (7.51)
11q	90	260 B	3420, 3350, 1660	$\text{C}_{22}\text{H}_{23}\text{N}_3\text{O}_2 \cdot \text{HCl} \cdot \text{H}_2\text{O}$ 415.91	63.12 (63.53)	6.40 (6.30)	9.97 (10.10)	8.50 (8.53)
11r	41	250 B	3290, 3095, 1645	$\text{C}_{23}\text{H}_{29}\text{N}_3\text{O}_2 \cdot \text{HCl} \cdot \text{H}_2\text{O}$ 429.93	64.29 (64.25)	6.71 (6.56)	9.32 (9.77)	8.25 (8.25)
11s	41	276 B	3460, 3350, 1645	$\text{C}_{23}\text{H}_{29}\text{N}_3\text{O}_2 \cdot \text{HCl} \cdot \text{H}_2\text{O}$ 445.93	62.18 (61.94)	6.33 (6.33)	9.69 (9.42)	8.10 (7.95)
11t	85	253 E	3360, 3150, 1650	$\text{C}_{25}\text{H}_{29}\text{N}_3\text{O}_2 \cdot \text{HCl} \cdot \text{H}_2\text{O}$ 506.00	59.25 (59.34)	6.35 (6.30)	0.40 (8.30)	7.30 (7.01)
11u	51	305 B	3300, 3100, 1640	$\text{C}_{22}\text{H}_{23}\text{N}_3\text{O}_2 \cdot \text{HCl}$ 413.89	64.05 (63.04)	6.08 (5.84)	10.30 (10.15)	0.72 (8.57)
11v	51	255 B	3400, 3300, 1650	$\text{C}_{26}\text{H}_{29}\text{N}_3\text{O}_2 \cdot \text{HCl} \cdot \text{H}_2\text{O}$ 465.96	66.71 (66.37)	6.06 (5.70)	9.02 (9.10)	
11w	63	247 B	3400, 3290, 1658	$\text{C}_{21}\text{H}_{21}\text{N}_3\text{O}_2 \cdot \text{HCl}$ 397.08	62.91 (63.23)	6.04 (5.01)	14.12 (14.05)	8.65 (8.89)
11x	60	275 B	3460, 3300, 1625	$\text{C}_{21}\text{H}_{21}\text{N}_3\text{O}_2 \cdot 2\text{HCl}$ 435.35	57.70 (57.93)	5.65 (5.56)	13.02 (12.87)	16.02 (16.29)
11z	61	244 B	3350, 3200, 1660	$\text{C}_{21}\text{H}_{21}\text{N}_3\text{O}_2 \cdot 2\text{HCl} \cdot 2\text{H}_2\text{O}$ 471.39	53.35 (53.50)	5.78 (5.99)	12.07 (11.89)	15.00 (15.04)


a) Recrystallization solvents: E = EtOH, W = water, A = CH_3CN , P = 2-propanol, D = diethyl ether.

Table 4. ¹H-NMR data of 6a–z (δ ppm, [D₆]DMSO)

2-H = 6.79–6.85 ; 3-H = 6.82–6.87 ; 4-H = 6.68–6.75 ; 1'-H = 2.62–2.70 ; 2'-H = 3.26–3.35 ; 3'-H = 8.24–8.41 ; 5'-H = 3.56–3.77 ; J_{2,6} = 1.5–2 Hz ; J_{5,6} = 8–8.5 Hz ; a) R = Me, CH₃ ; 3.69–3.70 ; b) R = Et, CH₃ ; 1.28–1.31 ; CH₂ = 3.93–4.01

R¹


2.56 (s, 3H, CH ₃)
4.33 (s, 2H, CH ₂) ; 7.34 (s, 5H, Ph)
3.72 (s, 3H, OCH ₃) ; 3.74 (s, 3H, OCH ₃) ; 4.25 (s, 2H, CH ₂) ; 6.8–7.0 (m, 3H, Ar)
7.5–7.8 (m, 3H, Ph-3', 4', 5'H) ; 8.0–8.2 (m, 2H, Ph-2', 6'H)
2.41 (s, 3H, CH ₃) ; 7.44 (d, 2H, Ph-3', 5'H) ; 7.98 (d, 2H, Ph-2', 6'H)
3.87 (s, 3H, OCH ₃) ; 7.16 (d, 2H, Ph-3', 5'H) ; 8.03 (d, 2H, Ph-2', 6'H)
3.77 (s, 3H, OCH ₃) ; 3.89 (s, 6H, 2xOCH ₃) ; 7.34 (s, 2H, Ph-2', 6'H)
5.24 (s, 2H, OCH ₂) ; 7.25 (d, 2H, Ph-3', 5'H) ; 7.44 (m, 5H, Ph) ; 8.04 (d, 2H, Ph-2', 6'H)
7.68 (m, 1H, Py-5'H) ; 8.47 (m, 1H, Py-6'H) ; 8.88 (m, 1H, Py-4'H) ; 9.25 (m, 1H, Py-2'H)
8.01 (m, 2H, Py-2', 6'H) ; 8.30 (m, 2H, Py-3', 5'H)
2.56 (s, 3H, CH ₃)
1.27 (t, 3H, CH ₃) ; 2.91 (q, 2H, CH ₂)
0.86 (t, 3H, CH ₃) ; 1.30 (m, 4H, 2xCH ₂) ; 1.69 (m, 2H, CH ₂) ; 2.88 (t, 2H, CH ₂)
0.85 (t, 3H, CH ₃) ; 1.31 (m, 4H, 2xCH ₂) ; 1.70 (m, 2H, CH ₂) ; 2.89 (t, 2H, CH ₂)
2.40 (m, 4H, 2xCH ₂ (H)) ; 2.71 (t, 2H, CH ₂ -C) ; 3.09 (t, 2H, CH ₂ -K) ; 3.54 (m, 4H, 2xCH ₂ (O))
1.2–2.0 (m, 10H, 5xCH ₂) ; 3.00 (m, 1H, cyclohexyl-1'H)
3.73 (s, 6H, 2xOCH ₃) ; 4.24 (s, 2H, CH ₂) ; 6.8–7.0 (m, 3H, Ar)
7.5–7.8 (m, 3H, Ph-3', 4', 5'H) ; 8.0–8.2 (m, 2H, Ph-2', 6'H)
2.42 (s, 3H, CH ₃) ; 7.45 (d, 2H, Ph-3', 5'H) ; 7.98 (d, 2H, Ph-2', 6'H)
3.87 (s, 3H, OCH ₃) ; 7.17 (d, 2H, Ph-3', 5'H) ; 8.04 (d, 2H, Ph-2', 6'H)
3.77 (s, 3H, OCH ₃) ; 3.90 (s, 6H, 2xOCH ₃) ; 7.34 (s, 2H, Ph-2', 6'H)
5.23 (s, 2H, OCH ₂) ; 7.25 (d, 2H, Ph-3', 5'H) ; 7.3–7.5 (m, 5H, Ph) ; 8.04 (d, 2H, Ph-2', 6'H)
7.5–7.8 (m, 2H, Ar) ; 8.0–8.3 (m, 4H, Ar) ; 8.80 (m, 1H, naphthyl-1'H)
7.72 (m, 1H, Py-4'H) ; 8.09 (m, 1H, Py-5'H) ; 8.24 (m, 1H, Py-6'H) ; 8.84 (m, 1H, Py-3'H)
7.68 (m, 1H, Py-5'H) ; 8.47 (m, 1H, Py-6'H) ; 8.88 (m, 1H, Py-4'H) ; 9.25 (m, 1H, Py-2'H)
8.01 (dd, 2H, Py-2', 6'H) ; 8.89 (dd, 2H, Py-3', 5'H)

Table 5. ¹H-NMR data of 7a–z (δ ppm, [D₆]DMSO)

2-H = 7.31–7.53 ; 3-H = 3.40–3.49 ; 4-H = 2.76–2.84 ; 5-H = 6.84–6.88 ; 6-H = 7.26–7.35 ; 9-H = 5.45–5.64 ; a) R = Me, CH₃ ; 3.79–3.86 ; b) R = Et, CH₃ ; 1.32–1.35 ; CH₂ = 4.06–4.12

R¹

2.55 (s, 3H, CH ₃)
4.29 (s, 2H, CH ₂) ; 7.35 (m, 5H, Ph)
3.74 (s, 3H, OCH ₃) ; 3.75 (s, 3H, OCH ₃) ; 4.20 (s, 2H, CH ₂) ; 6.8–7.0 (m, 3H, Ar)
7.5–7.7 (m, 3H, Ph-3', 4', 5'H) ; 8.0–8.2 (m, 2H, Ph-2', 6'H)
2.42 (s, 3H, CH ₃) ; 7.44 (d, 2H, Ph-3', 5'H) ; 8.03 (d, 2H, Ph-2', 6'H)
3.87 (s, 3H, OCH ₃) ; 7.16 (d, 2H, Ph-3', 5'H) ; 8.07 (d, 2H, Ph-2', 6'H)
3.77 (s, 3H, OCH ₃) ; 3.89 (s, 6H, 2xOCH ₃) ; 7.36 (s, 2H, Ph-2', 6'H)
5.25 (s, 2H, OCH ₂) ; 7.24 (d, 2H, Ph-3', 5'H) ; 7.43 (m, 5H, Ph) ; 8.07 (d, 2H, Ph-2', 6'H)
7.66 (m, 1H, Py-5'H) ; 8.49 (m, 1H, Py-6'H) ; 8.85 (m, 1H, Py-4'H) ; 9.31 (m, 1H, Py-2'H)
8.03 (dd, 2H, Py-2', 6'H) ; 8.87 (dd, 2H, Py-3', 5'H)
2.53 (s, 3H, CH ₃)
1.29 (t, 3H, CH ₃) ; 2.88 (q, 2H, CH ₂)
0.86 (t, 3H, CH ₃) ; 1.26 (m, 4H, 2xCH ₂) ; 1.73 (m, 2H, CH ₂) ; 2.76 (t, 2H, CH ₂)
0.84 (t, 3H, CH ₃) ; 1.26 (m, 4H, 2xCH ₂) ; 1.71 (m, 2H, CH ₂) ; 2.76 (t, 2H, CH ₂)
2.41 (s, 6H, 2xOCH ₃ (H)) ; 2.75 (m, 2H, CH ₂ -C) ; 3.06 (m, 2H, CH ₂ -C) ; 3.55 (m, 4H, 2xOCH ₂ (O))
1.3–2.1 (m, 10H, 5xCH ₂) ; 2.97 (m, 1H, cyclohexyl-1'H)
3.73 (s, 3H, OCH ₃) ; 3.74 (s, 3H, OCH ₃) ; 4.20 (s, 2H, CH ₂) ; 6.7–7.0 (m, 3H, Ar)
7.5–7.8 (m, 3H, Ph-3', 4', 5'H) ; 8.0–8.2 (m, 2H, Ph-2', 6'H)
2.42 (s, 3H, CH ₃) ; 7.44 (d, 2H, Ph-3', 5'H) ; 8.02 (d, 2H, Ph-2', 6'H)
3.87 (s, 3H, OCH ₃) ; 7.16 (d, 2H, Ph-3', 5'H) ; 8.07 (d, 2H, Ph-2', 6'H)
3.77 (s, 3H, OCH ₃) ; 3.90 (s, 6H, 2xOCH ₃) ; 7.36 (s, 2H, Ph-2', 6'H)
5.23 (s, 2H, OCH ₂) ; 7.24 (d, 2H, Ph-3', 5'H) ; 7.3–7.6 (m, 5H, Ph) ; 8.07 (d, 2H, Ph-2', 6'H)
7.6–7.8 (m, 2H, Ar) ; 8.0–8.3 (m, 4H, Ar) ; 8.80 (m, 1H, naphthyl-1'H)
7.67 (m, 1H, Py-4'H) ; 8.07 (m, 1H, Py-5'H) ; 8.27 (m, 1H, Py-6'H) ; 8.81 (m, 1H, Py-3'H)
7.67 (m, 1H, Py-5'H) ; 8.50 (m, 1H, Py-6'H) ; 8.86 (m, 1H, Py-4'H) ; 9.31 (m, 1H, Py-2'H)
8.05 (dd, 2H, Py-2', 6'H) ; 8.88 (dd, 2H, Py-3', 5'H)

Table 6. ¹H-NMR data of 11a–z (δ ppm, [D₆]DMSO). Structure in [D₆]DMSO

1-H = 7.34–7.58 ; 2-H = 8.60–9.10 ; 3-H = 8.72–9.23 ; 6-H = 4.05–4.32 ; 7-H = 2.96–3.06 ; 8-H = 7.04–7.09 ; 11-H = 7.13–7.43 ; a) R = Me, CH₃ ; 3.85–3.89 ; b) R = Et, CH₃ ; 1.36–1.39 ; CH₂ = 4.06–4.15

R¹

2.68 (s, 3H, CH ₃)
4.42 (s, 2H, CH ₂) ; 7.33 (m, 5H, Ph)
3.73 (s, 3H, OCH ₃) ; 3.74 (s, 3H, OCH ₃) ; 4.34 (s, 2H, CH ₂) ; 6.77 (dd, 1H, Ph-6'H)
6.92 (d, 1H, Ph-5'H) ; 6.96 (d, 1H, Ph-2'H)
7.6–7.9 (m, 5H, Ph)
2.42 (s, 3H, CH ₃) ; 7.42 (d, 2H, Ph-3', 5'H) ; 7.64 (d, 2H, Ph-2', 6'H)
3.87 (s, 3H, OCH ₃) ; 7.16 (d, 2H, Ph-3', 5'H) ; 7.72 (d, 2H, Ph-2', 6'H)
3.76 (s, 3H, OCH ₃) ; 3.82 (s, 6H, 2xOCH ₃) ; 7.08 (s, 2H, Ph-2', 6'H)
7.00 (d, 2H, Ph-3', 5'H) ; 7.59 (d, 2H, Ph-2', 6'H) ; 10.5 (bs, 1H, OH)
7.78 (dd, 1H, Py-5'H) ; 8.35 (m, 1H, Py-6'H) ; 8.89 (dd, 1H, Py-4'H) ; 9.01 (m, 1H, Py-2'H)
7.92 (dd, 2H, Py-2', 6'H) ; 8.96 (dd, 2H, Py-3', 5'H)
2.67 (s, 3H, CH ₃)
1.25 (t, 3H, CH ₃) ; 3.00 (q, 2H, CH ₂)
0.90 (t, 3H, CH ₃) ; 1.36 (m, 4H, 2xCH ₂) ; 1.73 (m, 2H, CH ₂) ; 2.97 (t, 2H, CH ₂)
0.87 (t, 3H, CH ₃) ; 1.30 (m, 4H, 2xCH ₂) ; 1.72 (m, 2H, CH ₂) ; 2.97 (t, 2H, CH ₂)
3.60 (bs, 6H, 3xCH ₂) ; 3.98 (m, 6H, 3xCH ₂) ; 11.70 (bs, 1H, OH)
1.4–2.0 (m, 10H, 5xCH ₂) ; 3.17 (m, 1H, cyclohexyl-1'H)
4.33 (s, 2H, CH ₂) ; 6.77 (dd, 1H, Ph-6'H) ; 6.92 (d, 1H, Ph-5'H) ; 6.95 (d, 1H, Ph-2'H)
7.65 (m, 5H, Ph)
2.42 (s, 3H, CH ₃) ; 7.41 (d, 2H, Ph-3', 5'H) ; 7.63 (d, 2H, Ph-2', 6'H)
3.86 (s, 3H, OCH ₃) ; 7.25 (d, 2H, Ph-3', 5'H) ; 7.72 (d, 2H, Ph-2', 6'H)
3.76 (s, 3H, OCH ₃) ; 3.82 (s, 6H, 2xOCH ₃) ; 7.07 (s, 2H, Ph-2', 6'H)
6.97 (d, 2H, Ph-3', 5'H) ; 7.58 (d, 2H, Ph-2', 6'H) ; 10.2 (bs, 1H, OH)
7.6–7.9 (m, 3H, Ar) ; 8.0–8.2 (m, 3H, Ar) ; 8.35 (bs, 1H, naphthyl-1'H)
7.69 (m, 1H, Py-4'H) ; 7.93 (m, 1H, Py-6'H) ; 8.15 (m, 1H, Py-5'H) ; 8.78 (m, 1H, Py-3'H)
7.85 (dd, 1H, Py-5'H) ; 8.43 (m, 1H, Py-6'H) ; 8.94 (dd, 1H, Py-4'H) ; 9.06 (d, 1H, Py-2'H)
7.99 (dd, 2H, Py-2', 6'H) ; 8.98 (dd, 2H, Py-3', 5'H)

4-Substituted 6,7-Dihydro-9,10-dialkoxy-2H-pyrimido[6,1-a]isoquinolin-2-imine Hydrochlorides (11b, c, e–z) (General method): A solution of the oxadiazole 7 (10 mmol) in a mixture of ethanol (200 ml) and 10% hydrochloric acid (10 ml) was hydrogenated over 8% palladium/carbon catalyst (0.2 g) until the uptake of hydrogen stopped. If the hydrochloride of the product precipitated hydrogenolysis was continued at 60°C and the catalyst filtered off at this temperature. The solvent was evaporated in vacuo and the residue crystallized to constant m.p. The [(benzyloxy)phenyl]oxadiazoles 7h and 7v absorbed two mol of hydrogen and gave the corresponding hydroxyphenyl compounds 11h and 11v. Yields, m.p.'s, solvents of crystallization, IR data, and elementary analyses were given in Table 3, ¹H-NMR data in Table 6.

CAS Registry Numbers

5a: 105361-71-5 / 5k: 107301-08-6 / 6a: 107300-85-6 / 6b: 107300-86-7 / 6c: 107300-87-8 / 6d: 105361-45-3 / 6e: 105361-47-5 / 6f: 105361-46-4 / 6g: 107300-88-9 / 6h: 107300-89-0 / 6i: 107300-90-3 / 6j: 107300-91-4 / 6k: 107300-92-5 / 6l: 107300-93-6 / 6m: 107300-94-7 / 6n: 107300-95-8 / 6o: 107300-96-9 / 6p: 107300-97-0 / 6q: 107300-98-1 / 6r: 107300-99-2 / 6s: 107301-00-8 / 6t: 107301-01-9 / 6u: 107301-02-0 / 6v: 107301-03-1 / 6w: 107301-04-2 / 6x: 107301-05-3 / 6y: 107301-06-4 / 6z: 107301-07-5 / 7a: 107301-11-1 / 7b: 107301-12-2 / 7c: 107301-13-3 / 7d: 107301-58-6 / 7e: 107301-09-7 / 7f: 107301-10-0 / 7g: 107301-14-4 / 7h: 107301-15-5 / 7i: 107301-16-6 / 7j: 107301-17-7 / 7k: 107301-18-8 / 7l: 107301-19-9 / 7m: 107301-20-2 / 7n: 107301-21-3 / 7o: 107301-22-4 / 7p: 107301-23-5 / 7q: 107301-24-6 / 7r: 107301-25-7 / 7s: 107301-26-8 / 7t: 107301-27-9 / 7u: 107301-28-8 / 7v: 107301-29-1 / 7w: 107301-30-4 / 7x: 107301-31-5 / 7y: 107301-32-6 / 7z: 107301-33-7 / 11a: 83733-79-3 / 11b: 107301-34-8 / 11c: 107301-35-9 / 11d: 107301-59-7 / 11e: 107301-36-0 / 11f: 107301-37-1 / 11g: 107301-38-2 / 11h: 107301-39-3 / 11i: 107301-40-6 /

11j: 107301-41-7 / **11k**: 107301-42-8 / **11l**: 107301-43-9 / **11m**: 107301-44-0 / **11n**: 107301-45-1 / **11o**: 107301-46-2 / **11p**: 107301-47-3 / **11q**: 107301-48-4 / **11r**: 107301-49-5 / **11s**: 107301-50-8 / **11t**: 107301-51-9 / **11u**: 107301-52-0 / **11v**: 107301-53-1 / **11w**: 107301-54-2 / **11x**: 107301-55-3 / **11y**: 107301-56-4 / **11z**: 107301-57-5 / MeCO₂Et: 141-78-6 / PhCH₂CO₂Et: 101-97-3 / 3,4-(MeO)₂-C₆H₃CH₂CO₂Et: 18066-68-7 / PhCO₂Et: 93-89-0 / 4-Me-C₆H₄CO₂Et: 94-08-6 / 4-MeOC₆H₄CO₂Et: 94-30-4 / 3,4,5-(MeO)₃-C₆H₂CO₂Et: 6178-44-5 / 4-PhCH₂OC₆H₄CO₂Et: 56441-55-5 / EtCO₂Et: 105-37-3 / Me(CH₂)₄CO₂Et: 123-66-0 / Me(CH₂)₆CO₂Et: 106-32-1 / 4-HOC₆H₄CO₂Et: 120-47-8 / R²CO₂Et (R² = 3-pyridyl): 614-18-6 / R²CO₂Et (R² = 4-pyridyl): 1570-45-2 / R²CO₂Et (R² = 2-morpholinoethyl): 20120-24-5 / R²CO₂Et (R² = cyclohexyl): 3289-28-9 / R²CO₂Et (R² = 1-naphthyl): 3007-97-4 / R²CO₂Et (R² = 2-pyridyl): 2524-52-9

¹⁾ Part I: D. Korbónits, P. Kiss, K. Simon, P. Kolónits, *Chem. Ber.* **117** (1984) 3183.

²⁾ ^{2a)} P. Kiss, S. Holly, *Chem. Ber.* **114** (1981) 61. — ^{2b)} K. Harsányi, P. Kiss, D. Korbónits, *J. Heterocycl. Chem.* **10** (1973) 435. —

^{2c)} P. Kiss, E. Pálosi, J. Szegi, J. Szentmiklósi, *VIIth. Int. Symp. on Medicinal Chemistry*, Torremolinos, Spain 1980, Abstr. p. 71.

³⁾ ^{3a)} B. Lal, A. N. Dohadwalla, N. K. Dadkar, A. D'Sa, N. Y. De Souza, *J. Med. Chem.* **27** (1984) 1470. — ^{3b)} A. Kaiser, F. Kienzle,

Eur.-Pat. Appl. 124.893 (5. May 1983) [*Chem. Abstr.* **102** (1984) P 78909x].

⁴⁾ I. Bata, G. Héja, P. Kiss, D. Korbónits, *J. Chem. Soc., Perkin Trans. 1*, **1986**, 9.

⁵⁾ Chinoín Gyógyszer és Vegyészeti Termékek Gyára R. T., Ger. Offen. 2,332,860 (30 June 1972) [*Chem. Abstr.* **80** (1974) P133434t].

⁶⁾ ^{6a)} D. Korbónits, E. M. Bakó, K. Horváth, *J. Chem. Research*, **1979** (S) 64; (M) 0801. — ^{6b)} D. Korbónits, I. Kanzel-Szvoboda, K. Horváth, *J. Chem. Soc., Perkin Trans. 1*, **1982**, 759. — ^{6c)} K. Horváth, D. Korbónits, G. Náray-Szabó, K. Simon, *J. Mol. Struct. (Theochem.)* **136** (1986) 215.

⁷⁾ This name was based on the Chemical Abstracts name of **11a** [*Chem. Abstr.* **98** (1983) Formula Index, 1370 F]. **11a** is the only representative of its type found in the literature (V. G. Granik, V. F. Knyazeva, I. V. Persianova, N. P. Solo'veva, R. G. Glushkov, *Khim. Geterosikl. Soedin.* **1982**, 1095 [*Chem. Abstr.* **98** (1983) 4513r]). No spectral data were reported and the quoted m.p. (> 300°C) is not in accord with our finding [275°C (dec.)].

⁸⁾ ^{8a)} D. Korbónits, K. Simon, P. Kolónits, *Tetrahedron Lett.* **24** (1983) 5763. — ^{8b)} D. Korbónits, P. Kolónits, *J. Chem. Soc., Perkin Trans. 1*, **1986**, 2163. — ^{8c)} R. Szebeni, D. Korbónits, *Tetrahedron Lett.* **1978**, 2049, and references cited therein.

[11/87]